In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer

Files

alhussan_abdulaziz_pharmaceutics_2024.pdf (1.59 MB)

Date

2024

Authors

Alhussan, Abdulaziz
Jackson, Nolan
Chow, Norman
Gete, Ermias
Wretham, Nicole
Dos Santos, Nancy
Beckham, Wayne
Duzenli, Cheryl
Chithrani, Devika B.

Journal Title

Journal ISSN

Volume Title

Publisher

Pharmaceutics

Abstract

This research underscores the potential of combining nanotechnology with conventional therapies in cancer treatment, particularly for challenging cases like pancreatic cancer. We aimed to enhance pancreatic cancer treatment by investigating the synergistic effects of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT) both in vitro and in vivo, utilizing a MIA PaCa-2 monoculture spheroid model and NRG mice subcutaneously implanted with MIA PaCa-2 cells, respectively. Spheroids were treated with GNPs (7.5 ?g/mL), DTX (100 nM), and 2 Gy of RT using a 6 MV linear accelerator. In parallel, mice received treatments of GNPs (2 mg/kg), DTX (6 mg/kg), and 5 Gy of RT (6 MV linear accelerator). In vitro results showed that though RT and DTX reduced spheroid size and increased DNA DSBs, the triple combination of DTX/RT/GNPs led to a significant 48% (p = 0.05) decrease in spheroid size and a 45% (p = 0.05) increase in DNA DSBs. In vivo results showed a 20% (p = 0.05) reduction in tumor growth 20 days post-treatment with (GNPs/RT/DTX) and an increase in mice median survival. The triple combination exhibited a synergistic effect, enhancing anticancer efficacy beyond individual treatments, and thus could be employed to improve radiotherapy and potentially reduce adverse effects.

Description

Keywords

docetaxel, gold nanoparticles, in vivo, pancreatic cancer, radiotherapy

Citation

Alhussan, A., Jackson, N., Chow, N., Gete, E., Wretham, N., Dos Santos, N., Beckham, W., Duzenli, C., & Chithrani, D. B. (2024). In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer. Pharmaceutics, 16(6), Article 6. https://doi.org/10.3390/pharmaceutics16060713

URI

https://doi.org/10.3390/pharmaceutics16060713
 https://hdl.handle.net/1828/20528

Collections

Faculty Publications (BioMed Central & Faculty of Science)
Faculty Publications (Medical Sciences)
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.